Category: News

Post

SCYNEXIS, Inc. Announces First Patient Dosed in Phase 3 Open-label Study Evaluating Oral Ibrexafungerp in Candida auris Infections (CARES)

Ibrexafungerp’s potent activity against multidrug-resistant fungal pathogen Candida auris confirmed in multiple pre-clinical studies Ibrexafungerp may provide a therapeutic option for this emerging pathogen classified as a serious global health threat by the CDC JERSEY CITY, N.J., Oct. 15, 2018 /PRNewswire/ — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening...

Post

Melinta Therapeutics Publishes Findings from Orbactiv® (oritavancin) Real-World Registry Demonstrating Efficacy and Safety Consistent with Phase 3 SOLO Program

NEW HAVEN, Conn. , Oct. 05, 2018 (GLOBE NEWSWIRE) — Melinta Therapeutics , Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, announced today that findings from the first phase of the ongoing Clinical READ FULL TEXT